Biogen touts new evidence from the gene therapy company it wagered $800M on
A year ago, Biogen made a big bet on a small gene therapy company. Now they have new evidence one of their therapies could work.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,400+ biopharma pros reading Endpoints daily — and it's free.